A Study Of PF-06664178 In Patients With Advanced Solid Tumors

Study summary

To assess the safety and tolerability at increasing dose levels of PF-06664178 in patients with advanced solid tumors in order to determine the maximum tolerated dose and select the recommended Phase 2 dose.

Ask AI to explain this study

Start here

Key things to know

Main goalTreatment

This describes the study’s primary purpose.

What is being studiedPF-06664178 and PF-06664178

The study team can explain what participation involves.

Who it may be forNeoplasms

These are broad labels—not an eligibility decision.

Checked against the public recordLast updated Feb 19, 2018 · Source: ClinicalTrials.gov

Is enrollment open?Terminated

Ask the study team to confirm whether enrollment is open.

What kind of study?Phase 1

Interventional

Where is it offered?10 U.S. locations

Locations may change over time.

Who runs it?Pfizer

Study sponsor

Study overview

What this study is about

Purpose: Treatment
Study type: Interventional
Phase: Phase 1
Sponsor: Pfizer
Interventions being studied: Drug: PF-06664178; Drug: PF-06664178

Explore related studies

How this study is categorized

These labels come from structured fields and exact terms in the public record.

Public criteria

Who may be able to participate

The sponsor separates these requirements into two groups. You do not need to interpret them alone—use them to guide a conversation with the study team.

Requirements people may need to meetInclusion criteria

Diagnosis of solid tumor that is advanced/metastatic and resistant to standard therapy or for whom no standard therapy is available
Performance Status of 0 or 1
Adequate bone marrow, kidney and liver function
Part 2 includes target expressing NSCLC, ovarian or breast cancer patients

Reasons someone may not be able to joinExclusion criteria

Brain metastases requiring steroids
Major surgery, radiation therapy, or systemic anti-cancer therapy within 4 weeks of study treatment start (6 weeks for mitomycin C or nitrosoureas)
Active and clinically significant bacterial, fungal, or viral infection

Important: This is the sponsor’s public criteria, not a determination of eligibility. The study team must review your individual situation.

Study sites

U.S. locations

Keck Hospital of USCLos Angeles, California
LAC&USC Medical CenterLos Angeles, California
USC/Norris Comprehensive Cancer Center / Investigational Drug ServicesLos Angeles, California
USC/Norris Comprehensive Cancer CenterLos Angeles, California
Anschutz Cancer PavilionAurora, Colorado
University of Colorado Denver CTO (CTRC)Aurora, Colorado
University of Colorado HospitalAurora, Colorado
Swedish Medical CenterSeattle, Washington
Seattle Cancer Care AllianceSeattle, Washington
University of Washington Medical CenterSeattle, Washington

Source and freshness
Processed from ClinicalTrials.gov. Last public update: Feb 19, 2018. Always confirm current availability with the study team.

View original record ↗